We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

89 hedge funds and large institutions have $134M invested in Adaptimmune Therapeutics in 2023 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 10

136% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 11

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

37% more funds holding

Funds holding: 65 → 89 (+24)

6% more capital invested

Capital invested by funds: $126M → $134M (+$7.47M)

0.98% less ownership

Funds ownership: 11.69% → 10.72% (-0.98%)

64% less call options, than puts

Call options by funds: $25K | Put options by funds: $70K

Holders
89
Holders Change
+24
Holders Change %
+36.92%
% of All Funds
1.4%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
34
Increased
26
Reduced
11
Closed
10
Calls
$25K
Puts
$70K
Net Calls
-$45K
Net Calls Change
-$28K

Top Buyers

Rank Fund Capital Flow
1
MAM
MPM Asset Management
Massachusetts
+$7.5M
2
MB
MPM BioImpact
Massachusetts
+$6.08M
3
TCM
Tang Capital Management
California
+$5.83M
4
LFCM
Long Focus Capital Management
Puerto Rico
+$2.83M
5
PHS
PFM Health Sciences
California
+$2.82M

Top Sellers

Rank Fund Capital Flow
1
ECM
Endurant Capital Management
California
-$1M
2
Bank of America
Bank of America
North Carolina
-$839K
3
Morgan Stanley
Morgan Stanley
New York
-$209K
4
VF
Virtu Financial
New York
-$96K
5
SEI Investments
SEI Investments
Pennsylvania
-$51.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
76
Osaic Holdings
Arizona
$2.09K +$1.26K +1,058 +88%
CUAMC
77
China Universal Asset Management Company
China
$1.77K -$62 -52 -3%
BNP Paribas Financial Markets
78
BNP Paribas Financial Markets
France
$1.58K +$709 +595 +53%
HWM
79
HighMark Wealth Management
Minnesota
$1.17K +$1.51K +1,269 New
CG
80
Cutler Group
California
$1K +$1.8K +1,511 New
US Bancorp
81
US Bancorp
Minnesota
$979 +$1.26K +1,058 New
FDCDDQ
82
Federation des caisses Desjardins du Quebec
Quebec, Canada
$698 +$900 +755 New
WAM
83
Worth Asset Management
Texas
$555 – – –
CHA
84
Carmichael Hill & Associates
Maryland
$486 – – –
IRC
85
Investors Research Corp
Georgia
$185 +$238 +200 New
BHWM
86
Beaird Harris Wealth Management
Texas
$86 +$110 +92 New
SIC
87
Salem Investment Counselors
North Carolina
$49 +$62 +52 New
VF
88
Virtu Financial
New York
– -$96K -88,234 Closed
SEI Investments
89
SEI Investments
Pennsylvania
– -$51.7K -47,409 Closed
VWM
90
Vigilare Wealth Management
Arizona
– -$31.4K -28,800 Closed
HF
91
HRT Financial
New York
– -$19K -18,047 Closed
COPPSERS
92
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$15.6K -14,287 Closed
State of Tennessee, Department of Treasury
93
State of Tennessee, Department of Treasury
Tennessee
– -$14.3K -13,100 Closed
ProShare Advisors
94
ProShare Advisors
Maryland
– -$11K -10,077 Closed
NA
95
NewEdge Advisors
Louisiana
– -$981 -900 Closed
CA
96
Clearstead Advisors
Ohio
– -$545 -500 Closed
ASN
97
Advisory Services Network
Georgia
– -$354 -325 Closed
Royal Bank of Canada
98
Royal Bank of Canada
Ontario, Canada
– +$155 +130 +448%
1 2 3
4

ADAP Hedge Fund Activity: Q2 2023 in Review

89 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2023, worth a combined $134M — up 5.9% from $126M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new ADAP positions and 10 closed out — a net gain of 24 holders — while 26 added to existing stakes and 11 trimmed.

The largest buyer was MPM Asset Management, opening a new position worth an estimated $7.5M. The largest seller was Endurant Capital Management, cutting an estimated $1M.

  • 89 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2023, up from 65 in Q1 2023.
  • Funds reported $134M of Adaptimmune Therapeutics stock for Q2 2023, up 5.9% quarter-over-quarter.
  • 34 funds opened new Adaptimmune Therapeutics positions in Q2 2023 and 10 closed out, a net change of +24 holders.
  • The largest Adaptimmune Therapeutics buyer in Q2 2023 was MPM Asset Management, an estimated $7.5M added.
  • The largest Adaptimmune Therapeutics seller in Q2 2023 was Endurant Capital Management, an estimated $1M sold.

Based on aggregated 13F filings for Q2 2023.